Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has disclosed its intellectual property patent applications filed in early 2021 for AP-188 has included novel salt forms of DMT.
Moreau telling Proactive in essence a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter. Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.